Prevention and regression of hypertension: Role of renal microvascular protection

Hiroyuki Sasamura, Kaori Hayashi, Kimiko Ishiguro, Hideaki Nakaya, Takao Saruta, Hiroshi Itoh

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Hypertension is a disease which affects over 26.4% of the world adult population, therefore novel approaches to the prevention and treatment of this disease need to be examined. Previous studies from our and other laboratories have shown that treatment of spontaneously hypertensive rats (SHR) and Dahl salt-sensitive rats with a renin-angiotensin system (RAS) inhibitor during the 'critical period' in hypertension development results in prevention of the later development of hypertension. In humans, Julius et al. reported similar findings in the landmark TROPHY study. Recently, we reported that 'pulse' treatment of SHR with high-dose angiotensin receptor blocker (ARB) is effective in causing sustained reduction of already established hypertension, even when the treatment was started after the 'critical period'. These results suggest the possibility that 'regression' of established hypertension may become feasible, and we have started a prospective, multicenter clinical study (STAR CAST study) to examine this possibility. In our animal studies, we found that treatment of rats during the 'critical period' with an ARB inhibits the development of renal arteriolar hypertrophy. Moreover, a high-dose angiotensin blocker caused a remarkable reversal of renal arteriolar hypertrophy in SHR, which was associated with changes in microvascular MMP expression. These results suggest that changes in the renal microvasculature may have an important role in the mechanisms of hypertension prevention and regression by ARB.

Original languageEnglish
Pages (from-to)658-664
Number of pages7
JournalHypertension Research
Volume32
Issue number8
DOIs
Publication statusPublished - 2009

Fingerprint

Renal Hypertension
Hypertension
Angiotensin Receptor Antagonists
Inbred SHR Rats
Kidney
Hypertrophy
Inbred Dahl Rats
Angiotensins
Renin-Angiotensin System
Microvessels
Matrix Metalloproteinases
Multicenter Studies
Pulse
Population

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Prevention and regression of hypertension : Role of renal microvascular protection. / Sasamura, Hiroyuki; Hayashi, Kaori; Ishiguro, Kimiko; Nakaya, Hideaki; Saruta, Takao; Itoh, Hiroshi.

In: Hypertension Research, Vol. 32, No. 8, 2009, p. 658-664.

Research output: Contribution to journalArticle

Sasamura, Hiroyuki ; Hayashi, Kaori ; Ishiguro, Kimiko ; Nakaya, Hideaki ; Saruta, Takao ; Itoh, Hiroshi. / Prevention and regression of hypertension : Role of renal microvascular protection. In: Hypertension Research. 2009 ; Vol. 32, No. 8. pp. 658-664.
@article{afa86c197e47477081e6cd363e7cb416,
title = "Prevention and regression of hypertension: Role of renal microvascular protection",
abstract = "Hypertension is a disease which affects over 26.4{\%} of the world adult population, therefore novel approaches to the prevention and treatment of this disease need to be examined. Previous studies from our and other laboratories have shown that treatment of spontaneously hypertensive rats (SHR) and Dahl salt-sensitive rats with a renin-angiotensin system (RAS) inhibitor during the 'critical period' in hypertension development results in prevention of the later development of hypertension. In humans, Julius et al. reported similar findings in the landmark TROPHY study. Recently, we reported that 'pulse' treatment of SHR with high-dose angiotensin receptor blocker (ARB) is effective in causing sustained reduction of already established hypertension, even when the treatment was started after the 'critical period'. These results suggest the possibility that 'regression' of established hypertension may become feasible, and we have started a prospective, multicenter clinical study (STAR CAST study) to examine this possibility. In our animal studies, we found that treatment of rats during the 'critical period' with an ARB inhibits the development of renal arteriolar hypertrophy. Moreover, a high-dose angiotensin blocker caused a remarkable reversal of renal arteriolar hypertrophy in SHR, which was associated with changes in microvascular MMP expression. These results suggest that changes in the renal microvasculature may have an important role in the mechanisms of hypertension prevention and regression by ARB.",
author = "Hiroyuki Sasamura and Kaori Hayashi and Kimiko Ishiguro and Hideaki Nakaya and Takao Saruta and Hiroshi Itoh",
year = "2009",
doi = "10.1038/hr.2009.85",
language = "English",
volume = "32",
pages = "658--664",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Prevention and regression of hypertension

T2 - Role of renal microvascular protection

AU - Sasamura, Hiroyuki

AU - Hayashi, Kaori

AU - Ishiguro, Kimiko

AU - Nakaya, Hideaki

AU - Saruta, Takao

AU - Itoh, Hiroshi

PY - 2009

Y1 - 2009

N2 - Hypertension is a disease which affects over 26.4% of the world adult population, therefore novel approaches to the prevention and treatment of this disease need to be examined. Previous studies from our and other laboratories have shown that treatment of spontaneously hypertensive rats (SHR) and Dahl salt-sensitive rats with a renin-angiotensin system (RAS) inhibitor during the 'critical period' in hypertension development results in prevention of the later development of hypertension. In humans, Julius et al. reported similar findings in the landmark TROPHY study. Recently, we reported that 'pulse' treatment of SHR with high-dose angiotensin receptor blocker (ARB) is effective in causing sustained reduction of already established hypertension, even when the treatment was started after the 'critical period'. These results suggest the possibility that 'regression' of established hypertension may become feasible, and we have started a prospective, multicenter clinical study (STAR CAST study) to examine this possibility. In our animal studies, we found that treatment of rats during the 'critical period' with an ARB inhibits the development of renal arteriolar hypertrophy. Moreover, a high-dose angiotensin blocker caused a remarkable reversal of renal arteriolar hypertrophy in SHR, which was associated with changes in microvascular MMP expression. These results suggest that changes in the renal microvasculature may have an important role in the mechanisms of hypertension prevention and regression by ARB.

AB - Hypertension is a disease which affects over 26.4% of the world adult population, therefore novel approaches to the prevention and treatment of this disease need to be examined. Previous studies from our and other laboratories have shown that treatment of spontaneously hypertensive rats (SHR) and Dahl salt-sensitive rats with a renin-angiotensin system (RAS) inhibitor during the 'critical period' in hypertension development results in prevention of the later development of hypertension. In humans, Julius et al. reported similar findings in the landmark TROPHY study. Recently, we reported that 'pulse' treatment of SHR with high-dose angiotensin receptor blocker (ARB) is effective in causing sustained reduction of already established hypertension, even when the treatment was started after the 'critical period'. These results suggest the possibility that 'regression' of established hypertension may become feasible, and we have started a prospective, multicenter clinical study (STAR CAST study) to examine this possibility. In our animal studies, we found that treatment of rats during the 'critical period' with an ARB inhibits the development of renal arteriolar hypertrophy. Moreover, a high-dose angiotensin blocker caused a remarkable reversal of renal arteriolar hypertrophy in SHR, which was associated with changes in microvascular MMP expression. These results suggest that changes in the renal microvasculature may have an important role in the mechanisms of hypertension prevention and regression by ARB.

UR - http://www.scopus.com/inward/record.url?scp=68349115029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68349115029&partnerID=8YFLogxK

U2 - 10.1038/hr.2009.85

DO - 10.1038/hr.2009.85

M3 - Article

C2 - 19521419

AN - SCOPUS:68349115029

VL - 32

SP - 658

EP - 664

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 8

ER -